





Novel probiotic *Levilactobacillus strain* as alternative approach for pets with cancer

<u>Context</u>: About 1/4 of dogs will develop at least one tumor during their lifetime while cancer treatments currently available (curative or palliative) remain insufficient or have significant limitations in terms of accessibility, cost and quality of life constraints. Thus, there is a huge need for alternative treating solutions and allowing the maintenance of a good quality of life, this latter being the main criterion sought by pet's owners.

Feb, 27th 2023

LUCKY

#Probiotics

#Cancer

#VeterinaryMedecine

Technology


► A specific *Levilactobacillus brevis strain* LBH1073 with unique anti-proliferative activities and anti-cancer properties

Applications

► Alternative approach in the form of a dietary supplement to treat cancer in pets, a life-threatening condition with huge clinical need

Key Advantages

- Easily accessible and non-invasive anti-cancer approach that might preserve the quality of life of the animal as well
- Genetically characterized strain
- Strain with QPS/GRAS status



Development stage

- ▶ Biochemical and functional *in vitro* assays using various cancer cell lines of different species demonstrating beneficial effects
- ▶ Proof-of concept obtained in *ex-vivo* models using canine cell lines and establishing significant tumor and metastasis regression
- ▶ in vivo results obtained in rodent demonstrating reduction of the tumors in a colorectal cancer model
- Mechanism of action characterized

Ø En savoir +

/// Intellectual Property

► Patent Application n°: WO2019/234076

/// Partner

INRA@

► Transfer strategy

We are looking for partner to license the technology for commercialization and/or to provide advice into refinement and clinical translation of the technology.